Application of Hibiscus flower extract in the preparation of drugs for the prevention or treatment of Cushing's syndrome

By using okra capsules or okra flower ethanol extract, the application gap of okra flower in the treatment of Cushing's syndrome was filled, achieving a significant reduction in cortisol and aldosterone levels, and providing a safe and effective drug for the treatment of Cushing's syndrome.

CN123059093APending Publication Date: 2026-11-10SUZHONG PHARMACEUTICAL GROUP CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510590840.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-08
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Currently, there is no literature documenting the use of okra capsules or the okra flower extract contained therein in the treatment of Cushing's syndrome, especially in Cushing's syndrome and adrenal adenoma and other diseases related to Cushing's syndrome.

Method used

Using okra capsules or the okra flower extract contained therein, especially the okra flower ethanol extract, to prepare a drug for the prevention or treatment of Cushing's syndrome, providing a safe and effective treatment option by significantly reducing cortisol and aldosterone levels.

Benefits of technology

Okra capsules or their Okra flower extract significantly reduce serum cortisol and aldosterone levels, demonstrating efficacy in treating hypercortisolism, while not significantly affecting corticosterone levels, thus providing a treatment option for diseases such as Cushing's syndrome.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention discloses the application of Hibiscus syriacus flower extract in the preparation of drugs for the prevention or treatment of hypercortisol-related diseases, belonging to the pharmaceutical field. It has the effect of lowering cortisol levels and has good safety, providing a better treatment option for patients with hypercortisol-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the pharmaceutical field and relates to the use of okra capsules or the okra flower extract contained therein in the preparation of medicaments for the prevention or treatment of diseases related to hypercortisolism, specifically the use of okra flower extract in the preparation of medicaments for the prevention or treatment of diseases related to hypercortisolism. Background Technology

[0002] Cushing's syndrome is a condition characterized by elevated circulating cortisol levels. High plasma cortisol levels can directly lead to pathological conditions, manifest as pathological signs, or have non-pathological characteristics.

[0003] Cushing's syndrome is a clinical syndrome characterized by hypercortisolism caused by pathologically increased cortisol synthesis and secretion from any cause. Common causes include pituitary tumors that secrete adrenocorticotropic hormone (ACTH) (Cushing's disease), ectopic ACTH secretion by non-pituitary tumors, adrenal adenomas, or adrenal carcinoma. Main manifestations include moon face, central obesity, plethora of facial features, hypertension, secondary diabetes, acne, purple striae, and osteoporosis. Long-term complications include diabetes, obesity, hypertension, fractures, kidney stones, and severe infections. Cushing's syndrome is a condition characterized by chronically excessive cortisol release.

[0004] The typical clinical manifestations of Cushing's syndrome are mainly due to the severe disturbances in glucose, fat, protein, and electrolyte metabolism caused by long-term hypercortisolism, which also interferes with the secretion of various other hormones. In addition, excessive secretion of ACTH and other adrenocortical hormones may also lead to corresponding clinical manifestations. Hypercortisolism affects the absorption of calcium in the small intestine, but bone tissue is mobilized, leading to increased bone calcium resorption and release. A large amount of calcium ions enters the bloodstream and is excreted in the urine. At this time, although blood calcium levels are at or slightly below the normal limit, urinary calcium excretion is increased, and high urinary calcium increases the risk of urinary tract stones. In addition to urinary calcium excretion, studies have also found elevated levels of phosphorus, potassium, uric acid, cystine, and oxalate in the urine of patients with Cushing's syndrome, while citrate levels are decreased. These urinary abnormalities also increase the risk of stone formation. Furthermore, systemic hypertension caused by hypercortisolism can also increase the risk of stone formation because hypertension leads to increased urinary calcium, oxalate, and uric acid excretion.

[0005] The medicinal Abelmoschi Corolla is the dried corolla of Abelmoschus manihot (L.) Medic., a plant of the Malvaceae family. It is sweet in taste, cold in nature, and acts on the kidney and bladder meridians. It has the effects of clearing damp-heat, detumescence and detoxification, and is used for treating carbuncles, furuncles and swelling toxins, scalds and burns. This medicinal material was first recorded in *Jiayu Bencao* (Materia Medica of Jiayu), which states: "Abelmoschi Corolla is mainly used to treat various malignant sores with persistent pus and fluid that do not heal for a long time, and is applied as a powder." *Compendium of Materia Medica* records: "Abelmoschi Corolla is sweet, cold, slippery and non-toxic in property and taste. It treats various malignant sores with persistent pus and fluid that do not heal for a long time, and will heal immediately when applied as a powder, making it an essential medicinal material for treating sores."

[0006] Huangkui Capsule is a commercially available Chinese patent medicine that has been on the market for a long time. Its main active ingredient is the ethanol extract of Abelmoschi Corolla, and it is used for the treatment of nephritis with good safety and no toxic side effects. Studies have confirmed that Abelmoschi Corolla is rich in chemical components, including flavonoids, polysaccharides, fatty oils, amino acids, organic acids, steroids, volatile components, inorganic elements, tannins, as well as alkaloids, proteins and the like.

[0007] At present, no literature has recorded the application of Huangkui Capsule or the Abelmoschi Corolla extract contained therein in medicaments for treating hypercortisolism. Content of the Invention

[0008] The objective of the present invention is to provide the application of Huangkui Capsule or the Abelmoschi Corolla extract contained therein in the preparation of a medicament for preventing or treating diseases associated with cortisol elevation. Experiments have proved that the Abelmoschi Corolla extract can significantly reduce the cortisol level with good safety, providing a better therapeutic medicament for patients with hypercortisolism.

[0009] To achieve the above objective, the technical solution adopted by the present invention is as follows:

[0010] In a first aspect, the present invention provides an application of Huangkui Capsule or the Abelmoschi Corolla extract contained therein in the preparation of a medicament for preventing or treating diseases associated with elevated cortisol levels. In some embodiments, the diseases are Cushing's syndrome and adrenal adenoma.

[0011] In a second aspect, the present invention provides an application of Huangkui Capsule or the Abelmoschi Corolla extract contained therein in the preparation of a medicament for preventing or treating hypercortisolism.

[0012] In a third aspect, the present invention provides an application of the Abelmoschi Corolla extract and the preparation thereof in the preparation of a medicament for preventing or treating hypercortisolism. Further, the present invention relates to the application of the Abelmoschi Corolla extract and the preparation thereof in the preparation of a medicament for preventing or treating Cushing's syndrome. Wherein, the Abelmoschi Corolla extract is selected from the Abelmoschi Corolla extract contained in Huangkui Capsule. In some technical solutions, the preparation is a granule.

[0013] The Huangkui Capsule described in the present invention is the Huangkui Capsule produced and sold by Suzhong Pharmaceutical Group Co., Ltd., which contains the ethanol extract of Abelmoschi Corolla with a total flavonoid content of about 8%.

[0014] As a further supplement to this invention, the invention also relates to the use of the ethanol extract of Hibiscus syriacus flower in reducing aldosterone levels. In some cases, the invention also relates to the use of the ethanol extract of Hibiscus syriacus flower in simultaneously reducing aldosterone and cortisol levels. The ethanol extract of Hibiscus syriacus flower contains more than 7% total flavonoids, and in some cases more than 50%, with one embodiment containing 68% total flavonoids (TFA).

[0015] Beneficial effects: The okra capsules of this invention, or the okra flower extract contained therein, can reduce serum cortisol levels and have a therapeutic effect on Cushing's syndrome. Furthermore, the okra capsules of this invention, or the okra flower extract contained therein, can significantly reduce aldosterone and cortisol levels without significantly affecting corticosterone levels. Attached Figure Description

[0016] Figure 1 Serum corticosterone levels in the Huang Kui capsule experiment.

[0017] Figure 2 Serum aldosterone levels in the Huang Kui capsule experiment.

[0018] Figure 3 Serum cortisol levels in the Huang Kui capsule experiment.

[0019] Figure 4 Blood glucose levels during the Huang Kui capsule experiment.

[0020] Figure 5 Systolic blood pressure in the Huang Kui capsule experiment.

[0021] Figure 6 Serum corticosterone levels in TFA.

[0022] Figure 7 Serum aldosterone levels in TFA.

[0023] Figure 8 Serum cortisol levels in TFA.

[0024] Figure 9 Weight status in the TFA experiment Figure 10 Blood glucose levels in the TFA experiment Figure 11 Systolic blood pressure in TFA test Detailed Implementation

[0025] The present invention will be further described in detail below with reference to specific embodiments. The following embodiments are not intended to limit the present invention, but only to illustrate the present invention. Unless otherwise specified, the experimental methods used in the following embodiments are generally performed under conventional conditions. Unless otherwise specified, the materials and reagents used in the following embodiments are commercially available.

[0026] The okra flowers in the following examples are dried okra corollas, and unless otherwise specified, they are from the same batch of okra flowers.

[0027] The extract of *Hibiscus syriacus* flowers can be obtained by direct extraction with high-concentration ethanol, followed by ethanol recovery and drying; alternatively, it can be refined into an extract of effective flavonoid components from *Hibiscus syriacus* flowers. In addition to detecting seven components—hyperoside, rutin, isoquercitrin, hibifolin-8-O-β-D-glucuronide, myricetin, quercetin-3'-O-glucoside, and quercetin—the extract of effective flavonoid components from *Hibiscus syriacus* flowers also includes the calculation of quercetin-3-O-locuoside content in the solid sample prepared in this embodiment of the invention, based on peak area. The content calculation method is: (peak area of ​​hyperoside reference standard / concentration of hyperoside reference standard * correction factor * peak area of ​​quercetin-3-O-locuoside * final volume / sample weight (based on dried product)). The content is not higher than 2.0%, further not higher than 0.9%, and preferably 0.1%-0.7%. The total content of various flavonoids detected was above 70%, further above 75%, and even further between 80% and 90%.

[0028] Unless otherwise specified, all percentages of ethanol mentioned in this invention refer to volume percentages.

[0029] The contents of seven components in the flavonoid extracts of *Hippophae rhamnoides* flowers prepared in each embodiment were determined. These seven components are: hyperoside, rutin, isoquercitrin, hibifolin-8-O-β-D-glucuronide, myricetin, quercetin-3'-O-glucosinolate, and quercetin. During the preparation of the effective fraction samples, the contents of each component in the solution before drying were also tested, and the contents of the samples changed before and after drying. The UPLC method reported in "Determination of Seven Components in *Hippophae rhamnoides* Flowers by One Test and Multiple Evaluation Method" (*Journal of Pharmaceutical Analysis*, 2013, Vol. 12, pp. 2082-2087) was used to determine the contents of the components.

[0030] Unless otherwise specified, the Huangqi capsules mentioned in the following examples are all Huangqi capsules produced and sold by Suzhou Zhongyao Pharmaceutical Group Co., Ltd.

[0031] Example 1: Preparation of Flavonoid Extract from Hibiscus Flower

[0032] 25 kg of Hibiscus rosa-sinensis flowers were crushed into coarse powder and extracted by percolation with 18 times the amount of 70% ethanol to obtain Hibiscus rosa-sinensis flower extract. The ethanol was removed from the extract, and it was diluted with water. Then, it was continuously extracted countercurrently with ethyl acetate at a solid-liquid ratio (extractant:extract) of 2.5:1, with four extraction stages. After solvent recovery under reduced pressure at 40°C, the extract was treated with D101 macroporous resin. The macroporous resin treatment process was as follows: macroporous resin diameter-to-height ratio of 1:5, and sample concentration of 0.15 g crude drug / mL. The sample volume was 3 BV, and the flow rate was 1.5 BV / h. Impurities were removed by 6 BV of pure water and 3 BV of 10% ethanol at a flow rate of 2 BV / h. Elution was then performed with 4 BV of 60% ethanol at a flow rate of 1.5 BV / h to obtain the eluent. The eluent was then subjected to reduced pressure at 60°C to recover the ethanol, yielding the Hibiscus syriacus flower extract. Seven specific components were added and adjusted (each component's content did not exceed 20% of the total weight) to achieve the contents shown in Table 1, thus preparing the Hibiscus syriacus flower flavonoid extract. The quercetin-3-O-sophoroside content was 0.20-0.50%.

[0033] Table 1

[0034]

[0035] Example 2: Preparation of flavonoid extract from Hibiscus syriacus flower

[0036] 30 kg of a mixture of yellow hibiscus flowers was pulverized into coarse powder and extracted by percolation with 18 times the amount of 70% ethanol to obtain a yellow hibiscus flower extract. The ethanol was removed from the extract, and it was diluted with water. Then, it was continuously extracted countercurrently with ethyl acetate at a solid-liquid ratio (extractant:extract) of 2.5:1, an injection rate of 80 mL / min, an extraction machine speed of 40 Hz, and four extraction stages. After solvent recovery under reduced pressure at 40°C, the extract was treated with D101 macroporous resin. The macroporous resin treatment process was as follows: macroporous resin diameter-to-height ratio of 1:5, sample concentration of 0.15 g crude drug / mL, sample volume of 5 BV, and a flow rate of 1.5 BV / h. Impurities were removed using 3 BV of pure water and 4 BV of 5% ethanol at a flow rate of 2 BV / h. Finally, 5 BV of... The eluent was obtained by eluting with 60% ethanol at a flow rate of 1.5 BV / h. The ethanol was recovered from the eluent under reduced pressure at 65℃ to obtain the total solids of Hibiscus syriacus flowers. The solids were then vacuum dried, pulverized, and the contents (%) of the seven components (flavonoids) were determined. The results are shown in Table 2 below. Among them, the contents of quercetin-3-O-acridin were 0.20-0.50%.

[0037] Table 2

[0038]

[0039] Example 3: Study on the effect of Abelmoschus manihot capsules on cortisol

[0040] 1) Experimental animals

[0041] Fifty 10-week-old male diabetic db / db mice and control db / m mice were purchased from the Institute of Model Animals, Nanjing University.

[0042] 2) Test methods

[0043] Mice were randomly divided into the db / db group and the db / db + okra capsule group (n=15 in each group, HKC group). Meanwhile, db / m mice served as a non-diabetic control group (n=15).

[0044] Based on the conversion of human and mouse body surface area, the contents of the okra capsules were dissolved in distilled water to a concentration of 0.5 g / ml, and administered by gavage at a dose of 0.84 g / kg / day (based on the weight of okra flower extract) for 4 weeks. db / db and db / m mice were given the same volume of distilled water. Body weight, blood pressure, and blood glucose levels were measured twice weekly. At the end of the administration period, serum cortisol levels were measured.

[0045] 3) Detection of serum steroid hormone levels

[0046] The levels of three major steroid hormones—aldosterone, corticosterone, and cortisol—in serum were detected using ELISA kits. Serum samples were centrifuged (1000×g, 15 min) within 30 minutes of collection, the supernatant was separated, aliquoted, and stored at -80℃ to avoid repeated freeze-thaw cycles. Aldosterone (ALD) and corticosterone (CORT) were analyzed using a competitive enzyme-linked immunosorbent assay (ELISA): for ALD, in microplates pre-coated with antibodies, aldosterone in the sample competed with biotinylated aldosterone for antibody binding, and the final OD value was negatively correlated with aldosterone concentration. For CORT, the solid-phase antibody competed with both biotinylated corticosterone and corticosterone in the sample, and the OD value decreased with increasing corticosterone concentration. Cortisol (Cor) was analyzed using a sandwich method: after cortisol was captured by a solid-phase antibody, it was developed by biotinylated antibody and enzyme-labeled avidin; the color intensity was positively correlated with cortisol concentration. The detection instrument was the Spark (TECAN) multi-functional microplate analyzer.

[0047] 4) Data Statistics and Analysis

[0048] Statistical analysis and graphing were performed using GraphPad Prism 5 software. Normality was analyzed using the Kolmogorov–Smirnov test. For one-way comparisons of means among multiple groups, one-way ANOVA followed by Tukey's multiple comparison test or Krushal-Wallis test followed by Dunn's multiple comparison test was used, depending on the normality of the data distribution. Quantitative data are expressed as mean ± standard deviation. P < 0.05 was considered statistically significant. Wherein, ns: no significant (statistically insignificant, P > 0.05); *: P < 0.05; **: P < 0.01; ***: P < 0.001; #: P < 0.05; ##: P < 0.01; ###: P < 0.001.

[0049] 5) Test Results

[0050] like Figure 1-3 As shown, in this study, serum aldosterone, corticosterone and cortisol levels were significantly elevated in db / db model mice. Treatment with Huangqi capsules significantly reduced aldosterone and cortisol levels, but did not significantly affect corticosterone levels.

[0051] Further histomorphological, transcriptomic, and steroid metabolomic studies revealed that *Abelmoschus manihot* capsules reduced aldosterone synthesis in the adrenal glands of db / db mice and decreased the thickness of the zona glomerulosa of the adrenal cortex. Given that aldosterone can induce inflammation and fibrosis through multiple mechanisms, inhibiting aldosterone synthase has become a novel intervention for treating secondary hypertension, myocardial fibrosis, and other aldosterone-related diseases. Its advantage lies in its ability to more completely inhibit the pathological effects induced by aldosterone, avoiding aldosterone effects independent of MR.

[0052] Compared with db / m mice, db / db mice had significantly higher body weight, blood glucose, and systolic blood pressure, while HKC treatment effectively reduced systolic blood pressure (P<0.05), but had no significant effect on body weight and blood glucose. Figure 4-6 ).

[0053] Example 4: Study on the effect of Hibiscus rosa-sinensis flower flavonoid extract (TFA) on cortisol.

[0054] 1) Experimental animals

[0055] Same as Example A.

[0056] 2) Test methods

[0057] TFA was prepared according to the method described in Example 9-1 above, and the dosage of TFA was 0.076 g / kg / day (based on the extract). The dosing cycle was 4 weeks.

[0058] 3) Detection of serum steroid hormone levels

[0059] Same as Example A.

[0060] 4) Test Results

[0061] like Figure 6-8 As shown, TFA treatment significantly reduced aldosterone levels but did not affect cortisol and corticosterone levels.

[0062] Compared with db / m mice, db / db mice had significantly higher body weight, blood glucose, and systolic blood pressure, while TFA treatment reduced systolic blood pressure (P<0.05), but had no significant effect on body weight and blood glucose. Figure 10-11 ).

[0063] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims.

Claims

1. The use of okra capsules or okra flower extract contained therein in the preparation of medicines for the prevention or treatment of diseases related to increased cortisol levels.

2. The application according to claim 1, characterized in that... The disease is Cushing's syndrome or adrenal adenoma.

3. The use of okra capsules or the okra flower extract contained therein in the preparation of drugs for the prevention or treatment of Cushing's syndrome.

4. The application of Hibiscus syriacus flower extract and its preparations in the preparation of drugs for the prevention or treatment of Cushing's syndrome, among which, The okra flower extract is selected from the okra flower extract contained in okra capsules, or the okra flower extract is prepared using the same preparation process as the okra flower extract contained in okra capsules.

5. The application of Hibiscus syriacus flower extract and its preparations in the preparation of drugs for the prevention or treatment of Cushing's syndrome, wherein, The okra flower extract is selected from the okra flower extract contained in okra capsules, or the okra flower extract is prepared by the same process as the okra flower extract contained in okra capsules.

6. The application according to any one of claims 3-5, characterized in that... The formulation is in the form of granules.

7. The application according to claim 1, characterized in that... The disease is accompanied by elevated aldosterone levels.

8. The use of okra capsules or okra flower extract contained therein in the preparation of medicines for the prevention or treatment of diseases related to elevated aldosterone levels.